JP2013513564A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513564A5
JP2013513564A5 JP2012542487A JP2012542487A JP2013513564A5 JP 2013513564 A5 JP2013513564 A5 JP 2013513564A5 JP 2012542487 A JP2012542487 A JP 2012542487A JP 2012542487 A JP2012542487 A JP 2012542487A JP 2013513564 A5 JP2013513564 A5 JP 2013513564A5
Authority
JP
Japan
Prior art keywords
oxy
methyl
pyridinyl
phenyl
imidazolidinedione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513564A (ja
JP5788404B2 (ja
Filing date
Publication date
Priority claimed from GB0921760A external-priority patent/GB0921760D0/en
Priority claimed from GBGB1012924.5A external-priority patent/GB201012924D0/en
Application filed filed Critical
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Publication of JP2013513564A publication Critical patent/JP2013513564A/ja
Publication of JP2013513564A5 publication Critical patent/JP2013513564A5/ja
Application granted granted Critical
Publication of JP5788404B2 publication Critical patent/JP5788404B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542487A 2009-12-11 2010-12-06 イミダゾリジンジオン誘導体 Expired - Fee Related JP5788404B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0921760.5 2009-12-11
GB0921760A GB0921760D0 (en) 2009-12-11 2009-12-11 Novel compounds
GBGB1012924.5A GB201012924D0 (en) 2010-07-30 2010-07-30 Novel compounds
GB1012924.5 2010-07-30
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives

Publications (3)

Publication Number Publication Date
JP2013513564A JP2013513564A (ja) 2013-04-22
JP2013513564A5 true JP2013513564A5 (enExample) 2014-02-06
JP5788404B2 JP5788404B2 (ja) 2015-09-30

Family

ID=43446689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542487A Expired - Fee Related JP5788404B2 (ja) 2009-12-11 2010-12-06 イミダゾリジンジオン誘導体

Country Status (16)

Country Link
US (7) US8722695B2 (enExample)
EP (1) EP2509961B1 (enExample)
JP (1) JP5788404B2 (enExample)
KR (1) KR101735675B1 (enExample)
CN (1) CN102753533B (enExample)
AU (1) AU2010330048B9 (enExample)
BR (1) BR112012015868A2 (enExample)
CA (1) CA2781685C (enExample)
DK (1) DK2509961T3 (enExample)
EA (1) EA019970B8 (enExample)
ES (1) ES2575215T3 (enExample)
IL (1) IL219628A (enExample)
MX (1) MX2012006615A (enExample)
PL (1) PL2509961T3 (enExample)
WO (1) WO2011069951A1 (enExample)
ZA (1) ZA201203233B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519176B1 (en) * 2009-10-05 2013-08-27 Boehringer Ingelheim International Gmbh Process for preparation of substituted P-aminophenol
PL2509961T3 (pl) 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
ES2560304T3 (es) 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
CN103974944B (zh) 2011-12-06 2016-11-02 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
EP2852588B8 (en) * 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013175215A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
PL3040329T3 (pl) * 2013-08-29 2019-04-30 Kyoto Pharma Ind Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości
LT3372584T (lt) 2014-12-19 2020-12-10 Aragon Pharmaceuticals, Inc. Diariltiohidantoino junginio gavimo būdas
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
CN105837453A (zh) * 2016-03-31 2016-08-10 常州大学 一种3,5-二氯-4’-硝基二苯醚的合成方法
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
CN108101811A (zh) * 2016-11-25 2018-06-01 斯福瑞（南通）制药有限公司 生产n-叔丁氧羰基-2-氨基-3,3-二甲基丁酸的方法
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
BR112019022493B1 (pt) 2017-05-02 2024-01-16 Fmc Corporation Composto, composições herbicidas, misturas herbicidas e métodos para controlar o crescimento de vegetação indesejada
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
WO2019222816A1 (en) 2018-09-21 2019-11-28 Bionomics Limited Substituted-pyridinyl compounds and uses thereof
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
KR102854594B1 (ko) 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
NZ775496A (en) 2018-11-30 2026-01-30 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
JP6870064B2 (ja) * 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
US12139473B2 (en) * 2019-03-25 2024-11-12 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof
MX2022009702A (es) 2020-02-06 2022-09-07 Autifony Therapeutics Ltd Moduladores de kv3.
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
GB2594931A (en) * 2020-05-06 2021-11-17 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
MX2024001899A (es) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd Moduladores del canal de potasio.
CN114605331A (zh) * 2022-03-17 2022-06-10 上海健康医学院 一种尼鲁米特及其中间体的制备方法
CN118974025A (zh) * 2022-03-28 2024-11-15 拜耳公司 取代的2-氨基嗪及其盐，及其作为除草活性物质的用途
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1147725A (en) * 1966-03-30 1969-04-02 Mitsui Kagaku Kogyo Kabushiki Novel halodiphenylethers for use as herbicides
US4099007A (en) * 1969-04-02 1978-07-04 Hoechst Aktiengesellschaft N,n-substituted 2,4,5-triketoimidazolidines and a process for their preparation
DE2916647A1 (de) * 1979-04-25 1980-11-06 Basf Ag Parabansaeurederivate
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
DK123493D0 (da) * 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6096895A (en) 1995-05-17 2000-08-01 E. I. Du Pont De Nemours And Company Heterocyclic dihydrazole compounds and their use for controlling fungal plant diseases
NZ310884A (en) 1995-06-20 1999-04-29 Du Pont Arthropodicidal and fungicidal cyclic amides
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
CZ184599A3 (cs) 1996-11-26 1999-09-15 E. I. Du Pont De Nemours And Company Methylem substituované fungicidy a artropodicidy
WO1998033382A1 (en) 1997-01-30 1998-08-06 E.I. Du Pont De Nemours And Company Fungicidal compositions
EP0966436B1 (de) * 1997-02-21 2002-12-11 Bayer Aktiengesellschaft Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2375982A1 (en) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Th2 differentiation inhibitors
AU2001244614A1 (en) 2000-04-04 2001-10-15 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
WO2001076582A1 (fr) 2000-04-05 2001-10-18 Shionogi & Co., Ltd. Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
GB0026838D0 (en) 2000-11-02 2000-12-20 Glaxo Group Ltd Treatment method
JPWO2003048134A1 (ja) 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
DE60322680D1 (de) 2002-02-07 2008-09-18 Univ Missouri Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
RU2356891C9 (ru) * 2002-05-16 2010-03-27 Байер Кропсайенс Аг Производные пиридинкарбоксамида и их соли для применения в качестве инсектицида
DE602004008762T2 (de) 2003-04-30 2008-06-12 The Institutes for Pharmaceutical Discovery, LLC, Branford Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
GB0413879D0 (en) 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
CA2608436C (en) 2005-05-13 2015-03-24 The Regents Of The University Of California Diarylhydantoin compounds and their use in the treatment of hyperproliferative disorders
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007103475A2 (en) 2006-03-07 2007-09-13 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
BRPI0715160A2 (pt) * 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
CA2684950A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009097997A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009097998A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
BRPI0924121A2 (pt) 2008-12-22 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
US20120142609A1 (en) 2009-06-26 2012-06-07 Abdoulaye Sene Non human animal models for increased retinal vascular permeability
PL2509961T3 (pl) 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
WO2011073114A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ES2560304T3 (es) * 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
EP2718285B1 (en) * 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
EP2852588B8 (en) * 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013175215A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors

Similar Documents

Publication Publication Date Title
JP6218808B2 (ja) Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
JP5572675B2 (ja) βセクレターゼ阻害作用を有する含硫黄複素環誘導体
US10308659B2 (en) Pyridine derivatives
RU2412937C2 (ru) Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестерилового эфира (сетр)
RU2634716C2 (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
US10787458B2 (en) Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines
CN118812519A (zh) 取代的四氢呋喃作为Nav1.8抑制剂
US10358435B2 (en) Triazolyl pyrimidinone compounds as PDE2 inhibitors
JP2013513564A (ja) イミダゾリジンジオン誘導体
US10160762B2 (en) 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
US20100087460A1 (en) Arylamide pyrimidone derivatives
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
US9815796B2 (en) Pyrimidone carboxamide compounds as PDE2 inhibitors
US10195201B2 (en) Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
US20250304546A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250243173A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250236602A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250388558A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250129035A1 (en) Compounds for the treatment of a central nervous system disease or disorder
EP4085054B1 (en) New pqsr inverse agonists
HK40002908B (zh) [1，2，3]三唑并[4，5-d]嘧啶衍生物
HK40002908A (en) Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives